# BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

> **NCT02137226** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 645 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** BI 695501
- **DRUG:** US-licensed Humira®

## Key facts

- **NCT ID:** NCT02137226
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-26
- **Primary completion:** 2016-03-03
- **Final completion:** 2016-10-18
- **Target enrollment:** 645 (ACTUAL)
- **Last updated:** 2018-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02137226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02137226, "BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02137226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*